Dr. Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, CEO of PGI Drug Discovery LLC, a company engaged in neuropsychiatric drug discovery with five partnered clinical programs including one in Phase III.  She also holds an  Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), the Business Review Board for the Alzheimer’s Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She currently serves on the Board of Directors of PsychoGenics Inc., the Board of Directors of Intensity Therapeutics, a clinical stage oncology company, the Board of Directors of Pasithea therapeutics, a public company focused on development of treatments for brain disorders and the Vice Chair of BioNJ.

Admitted to bar - 1970, Pennsylvania, and 1974, Connecticut; Princeton University, A.B., 1966; University of Michigan Law School, J.D., 1969; Dechert Price & Rhoads (Dechert – Philadelphia, PA), Associate, 1969-1973; Bergman, Horowitz & Reynolds (Withers Bergman - New Haven, CT), Associate, 1973-1978, Partner, 1978-1986 (Managing Partner, 1982-1986); First Spring Corporation (New York-based Bronfman family investment office), President, 1986-1995; BLS Strategic Capital, Inc. (Connecticut-based company providing wealth management and investment advisory services), President and Principal, 1995-2018; BLS Strategic Capital LLC (a Florida-based successor company providing wealth management and investment advisory  services), President and Principal, 2019-present; Balance Point Capital Partners (a private equity company providing equity capital and mezzanine debt to middle-market companies), Founding Partner, 2011-present; Chemwerth, Inc., Director, 1999-present; United Aluminum Corporation, Director, 2002-present; Calicraft LLC, Director, 2014-present; Alzeca Biosciences, Inc. Director, 2021-present.

Andrew Jarecki is an American filmmaker, musician, and entrepreneur. He is best known for the Emmy-winning 2015 documentary series The Jinx: The Life and Deaths of Robert Durst, which led to the arrest and imprisonment of Durst. He is also known for the documentary film Capturing the Friedmans, which won eighteen international prizes including the Grand Jury Prize at the Sundance Film Festival and the New York Film Critics Circle award, and was nominated for an Academy Award. He also co-founded Moviefone which provides film schedules over the Internet and telephone and was sold to AOL in 1999, and created the KnowMe iOS platform, a video editing and blogging app.  He is a graduate of Princeton University where he was a theatrical director.